Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study

被引:5
|
作者
Cui, Yuzhong [1 ,2 ,3 ,4 ,5 ]
Huang, Wei [6 ,7 ]
Du, Feng [5 ]
Yin, Xiaoyang [6 ,7 ]
Feng, Lei [6 ,7 ]
Li, Baosheng [6 ,7 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Tianjin 300060, Peoples R China
[2] Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China
[3] Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China
[4] Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China
[5] Zibo Municipal Hosp, Dept Oncol, Zibo 255400, Peoples R China
[6] Shandong First Med Univ & Shandong Acad Med Sci, Jinan 250117, Peoples R China
[7] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2022年 / 24卷 / 08期
基金
中国国家自然科学基金;
关键词
Esophageal cancer; In vivo; Niraparib tosylate; Preclinical; Radiosensitivity; DNA; RECOGNITION;
D O I
10.1007/s12094-022-02818-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Esophageal squamous cell carcinoma is associated with high morbidity and mortality rate for which radiotherapy is the main treatment modality. Niraparib, a Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) was previously reported to confer radiosensitivity in different malignancies including non-small cell lung cancer. In this study, we assessed the in vivo ability of niraparib in conferring radiosensitivity to esophageal squamous cell carcinoma cells. Materials and methods In this study, KYSE-30 and KYSE-150 cell lines were selected as in vivo esophageal squamous cell carcinoma models. The experimental groups were: niraparib tosylate alone, radiotherapy alone, control (no intervention), and combination therapy (radiotherapy + niraparib tosylate). Cell cytotoxicity assay, colony formation assay, flow cytometry, immunofluorescence, Western blotting, immunohistochemistry, lentivirus transfection analysis, and xenograft models were used for confirming radiosensitizing ability of niraparib and to investigate the possible cellular mechanism involved in radiosensitization. Results The colony formation efficiency of the combination group was significantly much lower than that of the single radiation group (P < 0.01). Cell cytotoxicity assay demonstrated a significant reduction in proliferation of irradiated cells after treatment with niraparib tosylate compared to niraparib tosylate alone (P < 0.01). Cell apoptosis significantly increased in the combination group compared to either niraparib tosylate or radiotherapy alone (P < 0.01). Rate of tumor suppression rate was significantly high in the combined treatment group (P < 0.01) but, significantly decreased in nude mice. Western blot and lentivirus infection model suggested overexpression of FANCG genes to confer radiosensitivity. Conclusion These results suggest that the synergistic effect of niraparib tosylate and radiation may be related to the down-regulation of FANCG.
引用
收藏
页码:1643 / 1656
页数:14
相关论文
共 50 条
  • [1] Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
    Yuzhong Cui
    Wei Huang
    Feng Du
    Xiaoyang Yin
    Lei Feng
    Baosheng Li
    Clinical and Translational Oncology, 2022, 24 : 1643 - 1656
  • [2] Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
    Yuzhong Cui
    Wei Huang
    Feng Du
    Xiaoyang Yin
    Lei Feng
    Baosheng Li
    Clinical and Translational Oncology, 2023, 25 : 560 - 562
  • [3] Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study (vol 24, pg 1643, 2022)
    Cui, Yuzhong
    Huang, Wei
    Du, Feng
    Yin, Xiaoyang
    Feng, Lei
    Li, Baosheng
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (02): : 560 - 562
  • [4] Circular RNAs With Efficacy in Preclinical In Vitro and In Vivo Models of Esophageal Squamous Cell Carcinoma
    Weidle, Ulrich H.
    Sela, Tatjana
    Brinkmann, Ulrich
    Niewoehner, Jens
    CANCER GENOMICS & PROTEOMICS, 2022, 19 (03) : 283 - 298
  • [5] Effects of photodynamic therapy for superficial esophageal squamous cell carcinoma in vivo and in vitro
    Kawazoe, Kaoru
    Isomoto, Hajime
    Yamaguchi, Naoyuki
    Inoue, Naoki
    Uehara, Ryohei
    Matsushima, Kayoko
    Ichikawa, Tatsuki
    Takeshima, Fuminao
    Nonaka, Takashi
    Nanashima, Atsushi
    Nagayasu, Takeshi
    Uehara, Masataka
    Asahina, Izumi
    Nakao, Kazuhiko
    ONCOLOGY LETTERS, 2010, 1 (05) : 877 - 882
  • [6] Melittin radiosensitizes esophageal squamous cell carcinoma with induction of apoptosis in vitro and in vivo
    Zhu, Hongcheng
    Yang, Xi
    Liu, Jia
    Ge, Yangyang
    Qin, Qin
    Lu, Jing
    Zhan, Liangliang
    Liu, Zheming
    Zhang, Hao
    Chen, Xiaochen
    Zhang, Chi
    Xu, Liping
    Cheng, Hongyan
    Sun, Xinchen
    TUMOR BIOLOGY, 2014, 35 (09) : 8699 - 8705
  • [7] Mechanism investigation of Forsythoside A against esophageal squamous cell carcinoma in vitro and in vivo
    Yang, Yingying
    Shen, Junru
    Deng, Peiyuan
    Chen, Ping
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [8] Curcumin: A new radio-sensitizer of squamous cell carcinoma cells
    Khafif, A
    Hurst, R
    Kyker, K
    Fliss, DM
    Gil, Z
    Medina, JE
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2005, 132 (02) : 317 - 321
  • [9] Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo
    Hara, F
    Aoe, M
    Doihara, H
    Taira, N
    Shien, T
    Takahashi, H
    Yoshitomi, S
    Tsukuda, K
    Toyooka, S
    Ohta, T
    Shimizu, N
    CANCER LETTERS, 2005, 226 (01) : 37 - 47
  • [10] Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo
    Liang, Feng
    Wang, Yu-Gang
    Wang, Changcheng
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 51 (03) : 1276 - 1286